Apyx Medical price target raised to $6 from $5 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Apyx Medical (APYX) to $6 from $5 and keeps a Buy rating on the shares. The firm notes the company reported a strong quarter with in-line sales and a beat on the bottom line. 2026 guidance exceeded the Street’s expectations and yet does not incorporate potential contribution from the liposuction handpiece approval which is expected mid-year. Lastly, expansion geographically via new country approvals and more affordable GLP-1s represent additional opportunities for the company to accelerate growth, Craig-Hallum adds.